Congress Activity					
Author	**Title**	**Study**	**Status**	**History**	**Target Submission date**
PAIN WEEK					
EXALGO					
T Moore et al	Steady-State Pharmacokinetics of Once-Daily Hydromorphone ER: A Randomized Study in Healthy Volunteers	PAI-1009	Poster final, awaiting final author approval	8/20: Awaiting final author approval, to print on Wednesday, 8/25 8/18: Poster approved with minor revisions by Covidien corporate 8/17: Reformatted poster sent to Covidien and authors for review 8/3: Poster being formatted **8/2: Abstract accepted for poster presentation** 7/20: Project Brief in Development 7/13: Submitted to PAINWeek, decision expected first week of August 7/2 Sent to Authors and Covidien for final review and approval 7/2 Comments incorporated, edit and fact check complete 5/25 Abstract approved by Author 5/24 Comments provided on abstract by Covidien	Meeting Date: September 8-11, 2010
D Taylor, M Hale, S Nalamachu	Results of an Open-Label Dose Conversion and Titration Study of Once-Daily Hydromorphone ER in Opioid-Tolerant Patients With Chronic Low Back Pain	NMT 1077-301	Poster under review with authors and Covidien	8/20: Draft poster circulated for review 8/17: First draft in development **8/4: Abstract accepted for poster presentation** 8/3: F/U with Dr. Taylor to confirm acceptance; first draft in development 7/13: Submitted to PAINWeek, decision expected first week of August 7/12: Reminder email sent to Covidien and Authors for comments 7/8: Sent to Authors and Covidien for final review and approval 7/7: Comments in from all Authors 7/1 Comments in from Jeff Patrick 6/29 Abstract circulated for reivew	Meeting Date: September 8-11, 2010
L Webster, B Bath, R Medve	The Effect of Pharmacokinetic Parameters on Euphoria and Drug Liking Following Different Oral Hydromorphone Formulations in Opioid-Experienced, Non-dependent, Recreational Drug Users	C-2004-022	Poster under review with authors and Covidien	8/23: Draft poster circulated for review 8/18: All data in, draft poster in development 8/17: Awaiting one final data set from Lifetree 8/12: Revised data tables delivered 8/11: First draft in development, awaiting revised tables 8/10: Conference call with Dr. Webster and Lifetree research 8/5: Received preliminary data **8/4: Abstract Accepted for Poster Presentation** 8/2: First-draft data analysis expected 8/5; teleconference scheduled with Lifetree for 8/10 to review data 7/27: Conference call with Lifetree 7/14: Submitted to PAINWeek, decision expected first week of August 7/13: F/U with Dr. Webster on disclosure information 7/9: Comments in from all authors 7/8: Re-send abstract to co-authors 7/7: F/U w/Authors for comments and disclosures 7/2: Sent to authors for final review and approval 7/2: Comments incorporated, edit and fact check complete 6/24 Comments provided on abstract by Covidien 6/23 Comments provided on abstract by Author	Meeting Date: September 8-11, 2010
M Hale, M Wallace, D Taylor, M Kutch, S Nalamachu	Safety and Tolerability of Once-Daily Hydromorphone ER in Adults With Moderate to Severe Chronic Noncancer and Cancer Pain: Pooled Analysis of 13 Clinical Trials	ISS	Layout with corporate, Covidien, and Authors for approval	8/23: To corpporate, Covidien, and authors for review and approval 8/20: Layout complete, final edit before circulation of final poster 8/19: Poster to layout 8/17: First draft of poster circulated to authors and Covidien for review 8/6: Dr. Taylor presenting in Dr. Hale's place at PAINWeek 8/3: First draft in development **8/2: Abstract accepted as a poster presentation** 7/13: Submitted to PAINWeek, decision expected first week of August 7/6 Final version sent for records 7/2 Sent to Authors and Covidien for final review and approval 7/2 Comments incorporated, edit and fact check complete 6/28 F/U with DT and MW, comments returned 6/24 Comments provided on abstract by Covidien 6/23 Abstract approved by Authors (MG and SN, awaiting DT comments)	Meeting Date: September 8-11, 2010

Author	Title	Study	Status	History	Target Submission date
Congress Activity					
S Nalamachu, D Taylor, M Hale	Safety and Tolerability of Once-Daily Hydromorphone ER in Opioid-Tolerant Adults With Moderate to Severe Chronic Non-cancer and Cancer Pain: Pooled Analysis of 11 Clinical Trials	ISS	Layout with corporate, Covidien, and Authors for approval	8/23: To corporate, Covidien, and authors for review and approval 8/20: Layout complete, final edit before circulation of final poster 8/19: Poster to layout 8/17: First draft of poster circulated to authors and Covidien for review 8/3: First draft in development **8/2: Abstract accepted as poster presentation** 7/13: Submitted to PAINWeek, decision expected first week of August 7/9 F/U with Covidien 7/8 F/U with Covidien for final approval 7/6 Sent to Covidien for review 6/28 F/U with DT and MW, comments returned 6/24 Comments provided on abstract by Covidien 6/23 Abstract approvd by Authors (MH and SN, awaiting DT comments)	Meeting Date: September 8-11, 2010
K Holman, S Mills, A Morelli, J Wang, M DeLuca, B Hollot, R Ruben, G Slatko	A Science-Based Approach to Responsible Risk Management for a Novel Long-Acting Opioid Analgesic	N/A	Layout in progress	8/18: Layout of text complete, awaiting finalization of figures 8/16: Approved poster text received by Synchrony; layout in progress 8/10: First draft in development 8/4: Abstract received	Meeting Date: September 8-11, 2010
PENNSAID					
S Roth, P Fuller	Topical diclofenac solution (PENNSAID®) compared with oral diclofenac in osteoarthritis of the knee: pooled analysis from 2 controlled clinical trials	PEN-03-112 and RA-CP-110	Layout in progress	8/19: Layout in progress 8/17: First draft of poster circulated to authors and Covidien for review 8/2: First draft of poster in development **7/22: Abstract accepted w/minor revision, revision made and resubmitted** 7/20: Project Brief in development 7/2 Submitted to PAINWeek, decision expected first week of August 6/24 Comments provided by Covidien 6/21 Comments provided by Author	Meeting Date: September 8-11, 2010
ACR					
PENNSAID					
B Galer	A Comparative Subjective Assessment Study of PENNSAID® and Voltaren Gel®, 2 FDA-Approved Topical Formulations of Diclofenac Sodium	R08-1039	Rejected	8/24: Rejected by ACR 6/28 Submitted: Decision expected in August 6/24 Comments provided on abstract by Covidien 6/23 Comments provided on abstract by Author	Meeting Date: November 7-11, 2010
S Roth, P Fuller	Topical Diclofenac Solution (PENNSAID®) Compared With Oral Diclofenac in Osteoarthritis of the Knee: Pooled Analysis From 2 Controlled Clinical Trials	PEN-03-112 and RA-CP-110	Accepted as a poster	**8/23: Accepted as a poster** 6/28 Submitted: Decision expected in August 6/24 Comments provided on abstract by Covidien 6/21 Comments provided on abstract by Author	Meeting Date: November 7-11, 2010
S Roth, P Fuller	Topical Diclofenac Solution With the Absorption Enhancer Dimethyl Sulfoxide (PENNSAID®) for the Treatment of Osteoarthritis of the Knee: Integrated Summary of Safety	ISS	Accepted as a poster	**8/23: Accepted as a poster** 6/28 Submitted: Decision expected in August 6/22 Comments provided on abstract by Covidien 6/21 Comments provided on abstract by Author	Meeting Date: November 7-11, 2010